Informasjon

Behandling av depresjon

Behandling av depresjon kan være i form av antidepressive medisiner, kognitiv terapi eller annen psykologisk behandling, elektrosjokkbehandling, eller lysterapi.

Sist oppdatert: 21.03.2023

Formålet med behandling

Behandlingen av depresjon skal redusere din sykdomsfølelse og øke lysten på livet. Formålet er også å forebygge at du blir syk igjen. Samtidig er det ønskelig at behandlingen gir deg minst mulig ubehag og plager.

Siden det ikke finnes noen direkte prøve eller test på depresjon, vil legen bruke andre mål på om du blir bedre eller verre:

Hvor sterke synes du eller behandleren at symptomene dine er?
Hvor godt fungerer du sammen med andre mennesker?
Hvor høyt skårer du på et livskvalitetsskjema?
Hvordan går det på jobben/ i hjemmet/ på skolen?
Har du selvmordstanker?
Har du ubehag av behandlingen?

Vil du vite mer?

Få tilgang på artikkelen om dette temaet fra Legehandboka.no

Artikkelen inneholder all informasjon norske allmennleger bruker i sitt daglige arbeid.

Jeg har lest og akseptert Brukervilkår ved kjøp av NEL-dokumenter

Dette dokumentet er basert på det profesjonelle dokumentet "Depresjon". Referanselisten for dette dokumentet vises nedenfor.

Helsedirektoratet. Nasjonal retningslinje for diagnostisering og behandling av voksne med depresjon i primær- og spesialisthelsetjenesten. Sist faglig oppdatert 13. juni 2022. www.helsedirektoratet.no
World Health Organization. Depression. Last updated 30 January 2020. www.who.int
Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-38. PMID: 23514317 PubMed
Gutiérrez-Rojas L, Porras-Segovia A, Dunne H, et al. Prevalence and correlates of major depressive disorder: a systematic review. Braz J Psychiatry. 2020 Nov-Dec;42(6):657-672. PMID: 32756809 PubMed
Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017 Feb;4(2):146-158. Epub 2016 Nov 15. PMID: 27856392. PubMed
Folkehelserapporten. Psykiske lidelser hos voksne. Folkehelseinstituttet. Sist oppdatert 03.12.2021. www.fhi.no
Bartlett EA, Zanderigo F, Shieh D, et al. Serotonin transporter binding in major depressive disorder: impact of serotonin system anatomy. Mol Psychiatry. 2022;27(8):3417-3424. PubMed
Moncrieff J, Cooper RE, Stockmann T, et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry 2022. pmid:35854107 PubMed
Peng W, Chen Z, Yin L, Jia Z, Gong Q. Essential brain structural alterations in major depressive disorder: A voxel-wise meta-analysis on first episode, medication-naive patients. J Affect Disord 2016; 199: 114-23. pmid:27100056 PubMed
Schmaal L, Veltman DJ, van Erp TG, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2016; 21: 806-12. pmid:26122586 PubMed
Mendenhall E, Kohrt BA, Norris SA, Ndetei D, Prabhakaran D. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. Lancet. 2017;389(10072):951-963. PubMed
Pearce M, Garcia L, Abbas A, et al. Association Between Physical Activity and Risk of Depression A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. pmid:35416941 PubMed
Bobo WV, Yawn BP. Concise review for physicians and other clinicians: postpartum depression. Mayo Clin Proc. 2014 ;89(6):835-44. doi: 10.1016/j.mayocp.2014.01.027 DOI
Okereke OI, Reynolds CF 3rd, Mischoulon D, et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2020 Aug 4;324(5):471-480. PMID: 32749491. PubMed
Nyström MB, Neely G, Hassmén P, et al. Treating Major Depression with Physical Activity: A Systematic Overview with Recommendations. Cogn Behav Ther 2015;44:341-52. pmid:25794191 PubMed
Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013 12;9:CD004366. doi: 10.1002/14651858.CD004366.pub6. The Cochrane Library
Wiles N, Thomas L, Turner N, et al. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for tretment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial. Lancet Psychiatry 2016
Furukawa TA, Suganuma A, Ostinelli EG, et al. Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. Lancet Psychiatry. 2021;8(6):500-511. PMID: 33957075 PubMed
Strauss C, Bibby-Jones A-M, Jones F, et al. Clinical Effectiveness and Cost-Effectiveness of Supported Mindfulness-Based Cognitive Therapy Self-help Compared With Supported Cognitive Behavioral Therapy Self-help for Adults Experiencing Depression The Low-Intensity Guided Help Through Mindfulness (LIGHTMind) Randomized Clinical Trial. JAMA Psychiatry 2023. pmid:36947058 PubMed
Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53. Journal of the American Medical Association
Stone MB, Yaseen ZS, Miller BJ, et al. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ 2022; 378: e067606. pmid:35918097 PubMed
Helsedirektoratet. Nasjonal faglig retningslinje om bruk av elektronkonvulsiv behandling - ECT. IS-2629. Oslo: Helsedirektoratet 2017. helsedirektoratet.no
Haq AU, Sitzmann AF, Goldman ML, et al. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76(10):1374-1384.
Rhee TG, Shim SR, Forester BP, et al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. pmid:36260324 PubMed
Aust S, Brakemeier E-L, Spies J, et al. Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression A Randomized Clinical Trial. JAMA Psychiatry 2022. pmid:35442431 PubMed
Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: A systematic review and meta-analyses. Am J Psychiatry 2016. PMID: 27113121 PubMed
Karyotaki E, Riper H, Twisk J, et al. Efficacy of Self-guided Internet-Based Cognitive Behavioral Therapy in the Treatment of Depressive Symptoms: A Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017. PMID: 28241179 PubMed
Karyotaki E, Efthimiou O, Miguel C, et al. Internet-Based Cognitive Behavioral Therapy for Depression A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry 2021; 78: 361-71. pmid:33471111 PubMed
Legeforeningen. Gjør kloke valg. Anbefalinger. Siden besøkt 11.02.2021 www.legeforeningen.no
Wiles N, Thomas L, Abel A, et al. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial. Health Technol Assess. 2014 May;18(31):1-168. PubMed
Cuijpers P, Oud M, Karyotaki E et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Ann Fam Med. 2021 May-Jun;19(3):262-270. PMID: 34180847.
Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. e-pub. The Lancet 2018. doi:https://doi.org/10.1016/S0140-6736(17)32802-7
Magni LR, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2013; 7: CD004185. pmid:24353997 PubMed
Breedvelt JJF, Warren FC, Segal Z, et al. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression An Individual Participant Data Meta-analysis. JAMA Psychiatry 2021; 78: 868-75. pmid:34009273 PubMed
Kovich H, Kim W, Quaste AM. Pharmacologic Treatment of Depression. Am Fam Physician. 2023;107(2):173-181. PubMed
Henssler J, Alexander D, Schwarzer G, et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022. PMID: 35171215 PubMed
Hollinghurst S, Carroll FE, Abel A, et al. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. Br J Psychiatry. 2014; 204: 69-76. PMID: 24262818 PubMed
Cipriani A, Smith K, Burgess S et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev, issue 4, 2006. The Cochrane Library
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58. PubMed
NICE Guideline. Depression in adults: recognition and management. Published 29 June 2022. www.nice.org.uk
Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2015. doi:10.1038/mp.2015.53 DOI
Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010: 167: 281-8.
Brent D, Emslie G, Clarke G et al. The TORDIA Randomized Controlled Trial. Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression. JAMA 2008; 299: 901-13. PubMed
Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No.: CD003944. DOI: 10.1002/14651858.CD003944.pub2. DOI
Rink L, Braun C, Bschor T, Henssler J, Franklin J, Baethge C. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry. 2018;79(3):17r11693.
Lagerberg T, Fazel S, Sjölander A, Hellner C, Lichtenstein P, Chang Z. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology. 2022;47(4):817-823. PubMed
Schjøtt J, Jahnsen JA. Venlafaksin og risiko for kardiovaskulære bivirkninger. Relis.no. Publisert 25.05.2016 relis.no
Szegedi A, Jansen WT, van Willingenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a metaanalysis including 6562 pateints. J Clin Psychiatry 2009; MID:19254516.
Cuijpers P, Oud M, Karyotaki E, et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Ann Fam Med. 2021;19(3):262-270. PubMed
Undurraga J, Baldessarini RJ. Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis. J Psychopharmacol. 2017;31(9):1184-1189. PubMed
Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601-609. PubMed
Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ. 2015;350:h517. Published 2015 Feb 18.
Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother. 2011;12(10):1623-1632. PubMed
Kessler DS, MacNeill SJ, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ. 2018. PMID: 30381374 PubMed
Lunde I, Langaas HC. Vortioksetin og graviditet. RELIS 2017. relis.no
Chen C, Shan W. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis. Psychiatry Res. 2019 Nov;281:112595. Epub 2019 Oct 2. PMID: 31627074. PubMed
Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014 ;348:g1888. doi: 10.1136/bmj.g1888 DOI
Seifritz E, Hatzinger M, Holsboer-Trachsler E. Efficacy of Hypericum extract WS(®) 5570 compared with paroxetine in patients with a moderate major depressive episode - a subgroup analysis published correction appears in Int J Psychiatry Clin Pract. 2017 Jun;21(2):160. Int J Psychiatry Clin Pract. 2016;20(3):126-132. PubMed
Maund E, Stuart B, Moore M et al. Managing Antidepressant Discontinuation: A Systematic Review. Ann Fam Med 2019; 17: 52-60. pmid:30670397 PubMed
Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167: 934-41. American Journal of Psychiatry
Furukawa T, Streiner DL, Young LT, Kinoshita Y. Antidepressants plus benzodiazepines for major depression. Cochrane Database of Systematic Reviews, Jan 2009. CD001026. Cochrane (DOI)
Edwards S, Hamilton V, Nherera L, et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess. 2013; 54:1-190. PMID: 24284258 PubMed
Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646. pmid:23814104 PubMed
Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-91. doi: 10.1001/jamapsychiatry.2014.1611 DOI
Hallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry. 2016. PMID: 27103682 PubMed
Chugh S, Chhabria A, Jung S, et al. Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract, 2018; 24 (1): 15-20. pmid:29320379 PubMed
Parsaik AK, Mascarenhas SS, Hashmi A, et al. Role of botulinum toxin in depression. J Psychiatr Pract, 2016; 22 (2); 99-110. pmid:27138078 PubMed
Brin MF, Durgam S, Lum A, et al. OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females. International Clinical Psychopharmacology 2020; 35 (1): 19-28. www.ncbi.nlm.nih.gov
Dean RL, Marquardt T, Hurducas C, Spyridi S, Barnes A, Smith R, Cowen PJ, McShane R, Hawton K, Malhi GS, Geddes J, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No.: CD011611. DOI: 10.1002/14651858.CD011611.pub3. Accessed 07 November 2022 The Cochrane Library
Abbar M, Dermattei C, El-Hage W, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ 2022; 376: e067194. pmid:35110300 PubMed
Raynder L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews, April 2010. CD007503.pub2. Cochrane (DOI)
Pjrek E, Friedrich ME, Cambioli L, et al. The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom. 2020;89(1):17-24. PubMed
Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015. doi:http://dx.doi.org/10.1136/bmj.h1798
Nielsen RE, Damkier P. Pharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview. Nord J Psychiatry. 2012;66(3):159-166. PubMed
Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339: b3569. BMJ (DOI)
Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med;2009:163, 949-54.
Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014; 348: f6932. BMJ (DOI)
Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309: 48-54. Journal of the American Medical Association
Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499-07.
Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015 ;30:4-20. doi: 10.1002/hup.2451 DOI
Coelho HF, Boddy K, Ernst E. Massage therapy for the treatment of depression: A systematic review. Int J Clin Pract 2008; 62: 325-33. PubMed
Dalgaard OS. Kurs i mestring av depresjon - en randomisert, kontrollert studie. Tidsskr Nor Lægeforen 2004; 124: 3043-6. PubMed
Jorm AF, Morgan AJ, Hetrick AE. Relaxation for depression. Cochrane Database of Systematic Reviews 2008; Issue 4. The Cochrane Library
Kallestad H, Langsrud K, Hansen B. Søvndeprivasjon som antidepressiv behandling. Tidsskr Nor Lægeforen 2007; 127: 1360-3. PubMed
Cuijpers P, van Straten A, Smit F, Mihalopoulos C. Beekman A. Preventing the onset of depressive distorders: A meta-analytic review of psychological interventions. Am J Psychiatry 2008; 165: 1272-80. American Journal of Psychiatry
Segal ZV, Dimidjian S, Beck A, et al. Outcomes of Online Mindfulness-Based Cognitive Therapy for Patients With Residual Depressive Symptoms. A Randomized Clinical Trial. JAMA Psychiatry. Published online January 29, 2020. jamanetwork.com
Castro A, Gili M, Ricci-Cabello I, et al. Effectiveness and adherence of telephone-administered psychotherapy for depression: A systematic review and meta-analysis. J Affect Disord. 2020;260:514-526. PubMed
Mohr DC, Ho J, Duffecy J, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. Telephone vs in-person therapy for depression. JAMA. 2012; 307 :2278-85.
Okumura Y, Ichikura K. Efficacy and acceptability of group cognitive behavioral therapy for depression: a systematic review and meta-analysis. J Affect Disord. 2014 ;164:155-64. doi: 10.1016/j.jad.2014.04.023.
Driessen E, Van HL, Don FJ, et al. The efficacy of cognitive-behavioral therapy and psychodynamic therapy in the outpatient treatment of major depression: A randomized clinical trial. Am J Psychiatry 2013; 170:1041-50 American Journal of Psychiatry
Brunoni AR, Valiengo L, Baccaro A, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry 2013; 70: 383-91. doi:10.1001/2013.jamapsychiatry.32 DOI
Myhre M. Atferdsaktivering for depresjon. Tidsskrift for Norsk psykologforening 2017; 54(5): 466-471. www.psykologtidsskriftet.no
Richards DA, Rhodes S, Ekers D, et al.. Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression. Health Technol Assess 2017 Aug; 21(46): 1-366. pmid:28857042 PubMed
Nussbaumer B, Kaminski-Hartenthaler A, Forneris CA, Morgan LC, Sonis JH, Gaynes BN, Greenblatt A, Wipplinger J, Lux LJ, Winkler D, Van Noord MG, Hofmann J, Gartlehner G. Light therapy for preventing seasonal affective disorder. Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD011269. DOI: 10.1002/14651858.CD011269.pub2 DOI
Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Høie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Archives of Women's Mental Health, November 2013.
Brunoni AR, Moffa AH, Fregni F, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016. PMID: 27056623 PubMed
Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med. 2017 Jun 29;376(26):2523-33. PMID: 28657871 PubMed
Berlim MT, Van den Eynde F, Daskalakis ZJ. A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychol Med. 2013;43(11):2245-54. doi: 10.1017/S0033291712002802.
Yesavage JA, Fairchild JK, Mi Z, et al. Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans A Randomized Clinical Trial. JAMA Psychiatry 2018. pmid:29955803 PubMed
Jiang J, Zhang C, Li C, et al. Magnetic seizure therapy for treatment-resistant depression. Cochrane Database Syst Rev. 2021 Jun 16;6:CD013528. doi: 10.1002/14651858.CD013528.pub2 DOI
Hamblin MR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clin. 2016;6:113-124. Published 2016 Oct 1. PMID: 27752476 PubMed
Salehpour F, Mahmoudi J, Kamari F, Sadigh-Eteghad S, Rasta SH, Hamblin MR. Brain Photobiomodulation Therapy: a Narrative Review. Mol Neurobiol. 2018;55(8):6601-6636. PubMed
Morriss R, Patel S, Boutry C, et al. Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. Lancet Psychiatry 2023. pmid:36724796 PubMed
Kuyken W, Warren FC, Taylor RS et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry 2016; 73(6): 565-74. pmid:27119968 PubMed
Kuyken W, Hayes R, Barrett B, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet. 2015. doi: 10.1016/S0140-6736(14)62222-4.
De Silva MJ, Cooper S, Li HL, et al. Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. Br J Psychiatry. 2013 ;202(4):253-60. doi: 10.1192/bjp.bp.112.118018 DOI
Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database of Syst Rev 2013; 2. DOI: 10.1002/14651858.CD001134.pub3. DOI
DeRubeis RJ, Zajecka J, Shelton RC, et al. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial published correction appears in JAMA Psychiatry. 2020 Jan 29;:. JAMA Psychiatry. 2020;77(3):237-245. PubMed
Bica T, Castelló R, Toussaint LL, Montesó-Curto P. Depression as a Risk Factor of Organic Diseases:An International Integrative Review. J Nurs Scholarsh. 2017;49(4):389-399. PubMed
Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-2312. PubMed
Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160: 3278-85. PubMed

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Annonsørinnhold

Annonsørinnhold fra Ascensia

Langtids glukose-sensor gir større frihet

Ny CGM-sensor som varer i opptil 6 måneder er nå tilgjengelig. For mange er tiden med hyppige bytter av sensor over!

Annonsørinnhold fra Helsedirektoratet

Utvidet samarbeid med Helsedirektoratet

Helsedirektoratet og Norsk Helseinformatikk utvider det eksisterende samarbeidet med mål om å bidra til kortere vei fra forskning til klinisk praksis. Gjennom utvidelsen av samarbeidet vil NHI i enda større grad bidra med å formidle viktige oppdateringer fra Helsedirektoratet.

Mest lest i dag

Barn

Behandling av depresjon

Hopp til innhold

Formålet med behandling

Er du helsepersonell?

Annonsørinnhold

Langtids glukose-sensor gir større frihet

Utvidet samarbeid med Helsedirektoratet

Mest lest i dag

Skarlagensfeber

Symptomer på infeksjon med coronavirus

Omgangssyke

Informasjon

Hold deg oppdatert

Behandling av depresjon

Hopp til innhold

Formålet med behandling

Er du helsepersonell?

Andre leste også dette

Annonsørinnhold

Mest lest i dag